BPH-1358

• Description:

  BPH-1358 (NSC50460) is a potent human farnesyl diphosphate synthase (FPPS) and undecaprenyl diphosphate synthase (UPPS) inhibitor with IC50s of 1.8 μM and 110 nM, respectively, and is active against S. aureus in vitro (MIC ~250 ng/mL) [1][2].

• Product Name Alternative:

  NSC50460

• UNSPSC:

  12352005

• Target:

  Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/bph-1358.html

• Purity:

  99.12

• Solubility:

  DMSO : 4.04 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C(C1=CC=C(C2=CC=C(C(NC3=CC=CC(C4=NCCN4)=C3)=O)C=C2)C=C1)NC5=CC=CC(C6=NCCN6)=C5.[H]Cl.[H]Cl

• Molecular Formula:

  C32H30Cl2N6O2

• Molecular Weight:

  601.53

• References & Citations:

  [1] Liu YL, et al. Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries. ACS Med Chem Lett. 2015 Jan 29;6 (3) :349-54.|[2]Zhu W, et al. Antibacterial drug leads: DNA and enzyme multitargeting. J Med Chem. 2015 Feb 12;58 (3) :1215-27.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [5352-53-4]